NEWS RELEASE
18th Sep 2018, Hyderabad, India

Aurobindo Pharma receives approval from South African Health Products Regulatory Authority for latest fixed dose triple combination tablets

Aurobindo Pharma Limited is pleased to announce that the company has received approval from the South African Health Products Regulatory Authority (SAHPRA) for its Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (DLT) tablets, 50mg/300mg/300mg, the first-line preferred regimen for HIV patients as per latest WHO guidelines.

Aurobindo is now among the first few companies which has received approval for this product. This approval demonstrates our commitment towards HIV patients and enables the company to participate in South African HIV tender as well as launch in private market. The approval further strengthens Aurobindo's HIV product basket in South Africa, which has the potential to improve the lives of millions of patients.

Prior to SAHPRA's approval, Aurobindo has received tentative approval for the drug from US Food and Drug Administration and launched in Sub-Saharan African markets as part of its commitment to bring affordable HIV drugs to millions of patients globally.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

For further information, please contact:

Krishna Kiran
Investor Relations
Phone: 040-66725401 / 66725000
Mobile: +91 98486 67906
Email: ir@aurobindo.com

Disclaimer:

This press release contain statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch , implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.